ALFA Finder| Management target | Revenue 60.0% FY27 |
|---|
| Revenue growth | 16% in FY26; 60%+ target for FY27. |
|---|---|
| Margins | EBITDA margin improved from 25.35% to 28.45% YoY. |
| Order book | ₹47.46 Cr order from a PSU pending execution. |
| Demand visibility | Strong; secured ₹47.46 Cr PSU order recently. |
| Management confidence | High; citing successful IPO and growth strategy execution. |
Growth
FY26 Revenue reached ₹52.51 Cr (+16% YoY); PAT grew 23% to ₹8.75 Cr.
Outlook
Guided at least 60% revenue growth for FY27; investing ₹30.18 Cr in fully automated Noida facility by Oct-26.
Risks
Lengthy CDSCO regulatory processes (9-12 months per product) create significant entry barriers and timeline dependencies.
Investor Presentation filed with NSE, NSE: AVIENCE. Summary written with AI assistance from the document.
Avience Biomedicals Ltd: key numbers
- Share price
- ₹262.40
- Market cap
- ₹143.9 Cr
- Revenue (annual)
- ₹52.51 Cr
- Net profit (annual)
- ₹8.75 Cr
- P/E (TTM)
- 16.4×Sector 54.5×
- Promoter holding
- 64.59%
- FII holding
- 0.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Avience Biomedicals Ltd
All →Avience Biomedicals H1 FY27 Results: Net Profit ₹5.5 Cr, Up 22.2% YoY
Avience Biomedicals Ltd reported revenue from operations of ₹31.1 Cr (+16.0% YoY) and net profit of ₹5.5 Cr (+22.2% YoY) for H1 FY27.
- Key figure
- Net profit ₹5.5 Cr · +22.2% YoY
Avience Biomedicals Other Announcement
Avience Biomedicals confirmed corporate governance compliance is not applicable, as it is SME-listed on NSE Emerge. No quarterly governance report is required for September 2026.
Avience Biomedicals Other Announcement
Avience Biomedicals Limited has appointed M.A.M and Associates, GR Gupta & Associates, and V C A N & Co LLP as its statutory, secretarial, and internal auditors.
Avience Biomedicals Annual General Meeting
Avience Biomedicals Limited held its 7th AGM on September 30, 2026. Shareholders approved borrowing limits up to ₹100 Crore and the appointment of new statutory auditors.
Avience Biomedicals Annual General Meeting
Avience Biomedicals Limited has scheduled its 7th Annual General Meeting for September 30, 2026. The company also announced book closure dates for the AGM.
Avience Biomedicals Other Announcement
The company informed shareholders about accessing the 7th AGM Notice and Annual Report via web links and requested KYC updates for those with unregistered emails.